Evidence map›Paper›PMID 42502814›Full record

ArticleMaterials today. Bio2026

An orally administered biohybrid complex leveraging probiotic guidance to treat colorectal cancer via

Wenfei Fan, Shuaiguang Li, Xue Wang, Jingya Xu, Shan Jiang, Haixia Shen, Yanran Yue, Zhonghua Dong, Xuan Wang, Haiping Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenfei FanDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Shuaiguang LiDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Xue WangDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Jingya XuDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Shan JiangDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Haixia ShenSchool of Pharmacy, The Shandong Second Medical University, Weifang, Shandong, 261053, China.
Yanran YueDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Zhonghua DongDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Xuan WangDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
Haiping HuDepartment of Pharmacy, The Second Affiliated Hospital of Shandong First Medical, University, Tai'an, Shandong, 271000, China.
Wei XuDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral therapy for colorectal cancer (CRC) holds inherent promise for enhancing patient compliance and enabling gastrointestinal targeting, while its application is hampered by low oral drug utilization efficiency and precise colonic localization. This study developes an orally delivered biohybrid complex, CS@CB-Lipo@5-FU/R837, which leverages the hypoxic tropism of the probiotic

Indexed as

Chemo-immunotherapyColorectal cancerIn situ vaccineProbiotic-guided deliveryTumor immune microenvironment

Identifiers

PMID42502814
PMCPMC13400377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.